Abstract
Fluorinated pyrimidines such as 5FU, ftoraful and UFT are widely used in Japan and have a biggest share in the market of anticancer drugs and they have been mainly used for the treatment of gastrointestinal malignancies such as stomach cancer and colon cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
M. Bungo, Y. Fujiwara, K. Kasahara, K. Nakagawa, Y. Ohe, Y. Sasaki, S. Irino and N. Saijo, Decreased accumulation as a mechanism of resistance to cisdiamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA darnage and repair., Cancer Res., 50: 2549, (1990).
B. A. Chabner, Pyrimidine antagonists. In pharmacologic basis of Cancer Treatment, B. A. Chabner(ed) pp 183–212. The W. B. Saunders CO.: Philadelphia, (1981).
C. Heiderberger, P. V. Danenberg, and R. G. Moran, Fluorinated pyrimidines and their nucleosides. In advances in enzymology and related areas in molecular biology. A. Meister(ed.) pp 57–119 John Wiley & Sons: New York. (1983).
W. S. Hong, N. Saijo, Y. Sasaki, K. Minato, H. Nakano, K. Nakagawa, Y. Fujiwara, K. Nomura, and P. R. Twentyman, Establishment and characterization of cisplatin resistant sublines of human lung cancer cell lines., Int. J. Cancer., 41: 462, (1988).
J. Houghton, C. Schmidt, and P. J. Houghton, The effect of derivates of folic acid on the fluorodeoxyuridylate-thymidylate symthase covalent complex in human colon xenografts., Eur. J. Clin. Oncol, 18: 347. (1982).
R. G. Moran, C. P. Spears, C. Heidelberger, Biochemical determination of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5 fluoro-2′-deoxyuridate, 2′-deoxyuridate, and thymidylate synthase., Proc. Natl. Acid. Sci, 76: 1456, (1979).
P. J. O’Dwyer, M. J. Comfeld, R. Peler, and R. L. Comis, Phase I trial of 5-fluorouracil, leucovorin and cisplatin in combination., Cancer Chemother. Phannacol., 27: 131, (1990).
Y. Ohe, Y. Sugimoto, and N. Saijo, Collateral sensitivity of cisplatin-resistant human non-small lung cancer cell lines to thymidylate synthase inhibitors., Cancer J., 3: 332, (1990).
Y. Ohe, T. Shinkai, K. Eguchi, Y. Sasaki, T. Tamura, K. Nakagawa, A. Kojima, K. Yamada, F. Oshita, T. Miya, and N. Saijo, Nagative phase Il study of S-fluorouracil and high dose leucovorin in non-small cell lung cancer., Jpn. J. Clin. Oncol., 20: 364, (1990).
K. J. Scanlon, R. L. Safirstein, H. Thies, R. B. Gross, S. Waxman, and J. B. Guttenplan, Inhibition of amino acid transport by cis-diamminedichloroplatinurn derivatives in L1210 murine leukemia cells., Cancer Res., 42: 4211, (1983).
K. J. Scanlon, E. M. Newman, Y. Lu, and D. G. Priest, Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells., Proc. Natl. Acid. Sci., 83: 8923, (1986).
T. Shirasaka, Y. Shimamoto, H. Ohshimo, H. Saito, and M. Fukushima., Metabolic basis of the synergistic antitumor activities of 5-fluorovracil and cisplatin in rodent tumor models in vivo., Personal communications.
Y. Sugimoto, Y. Ohe, K. Nishio, T. Ohmori, T. Morikage, Y. Fujiwara, and N. Saijo, Mechanism of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small cell lung cancer cell line., Br. J. Cancer, 65: 857, (1992-a).
Y. Sugimoto, Y. Ohe, K. Nishio, T. Ohmori, Y. Fujiwara, and N. Saijo, In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines., Cancer Chemother. Pharmacol, 30: 417, (1992-b).
E. E. Vokes. K. E. Choi, R. L. Schilsky, W. J. Moran, C. M. Guarnieri, R. R Weichselbaum, and R. R Ranje, Cisplatin, fluorouracil, and high dose leucovorin for recurrent or metastatic head and neck cancer., J. Clin. Oncol., 6: 618, (1988).
E. E. Vokes, R. L. Schilsky, R. R. Weichselbaum, M. F. Kazloff, and W. P. Panje, Induction chemotherapy with CDDP, 5FU and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis., J. Clin. Oncol., 8: 241, (1990).
E. E. Vokes, M. Rosemarie, E. P. Lester, W. R. Panje, and R. R. Weichselbaum, Cisplatin and fluorouracil chemotherapy does not yeild long-term benefit in locally advanced head and neck cancer: Results from a single institution., J. Clin. Oncol., 9: 1376, (1991).
F. E. Vokes, R. R. Weichselbaum, R. Mick, J-M. McEvilly, D. J. Harof, and W. R. Panje, Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer., J. Natl Cancer Inst., 84: 877, (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Saijo, N., Sugirnoto, Y. (1993). Rationale for the Combination Therapy of 5FU and CDDP. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_22
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive